XBiotech (XBIT) 10-K 16 Mar 18 2017 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Mar. 15, 2018
Document Information [Line Items]
Entity Registrant Name	XBiotech Inc.
Entity Central Index Key	1,626,878
Trading Symbol	xbit
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		35,439,272
Entity Public Float	$ 139,630,732
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 31,768	$ 34,324
Prepaid expenses and other current assets	1,564	2,606
Total current assets	33,332	36,930
Property and equipment, net	29,640	10,142
Building construction in progress		19,978
Total assets	62,972	67,050
Current liabilities:
Accounts payable	1,730	4,431
Accrued expenses	1,062	3,532
Total current liabilities	2,792	7,963
Long-term liabilities:
Deferred rent	18	23
Total liabilities	2,810	7,986
Shareholders’ equity:
Preferred Stock, no par value, unlimited shares authorized, no shares outstanding	0	0
Common stock, no par value, unlimited shares authorized, 35,439,272 and 32,627,691 shares outstanding at December 31, 2017 and December 31, 2016, respectively	277,492	242,419
Accumulated other comprehensive loss	(768)	57
Accumulated deficit	(216,562)	(183,412)
Total shareholders’ equity	60,162	59,064
Total liabilities and shareholders’ equity	$ 62,972	$ 67,050

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares $ / shares in Thousands	Dec. 31, 2017	Dec. 31, 2016
Preferred stock, par value (in dollars per share)	$ 0	$ 0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0	$ 0
Common stock, shares outstanding (in shares)	35,439,272	32,627,691

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Operating expenses:
Research and development	$ 26,424	$ 42,486	$ 31,310
General and administrative	7,635	10,277	6,200
Total operating expenses	34,059	52,763	37,510
Loss from operations	(34,059)	(52,763)	(37,510)
Other income (loss):
Interest income	354	49
Other income			21
Foreign exchange gain (loss)	555	(47)	6
Total other income (loss)	909	2	27
Net loss	$ (33,150)	$ (52,761)	$ (37,483)
Net loss per share—basic and diluted (in dollars per share)	$ (0.95)	$ (1.63)	$ (1.22)
Shares used to compute basic and diluted net loss per share (in shares)	34,875,814	32,403,391	30,801,994

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Net loss	$ (33,150)	$ (52,761)	$ (37,483)
Foreign currency translation adjustment	(825)	258	(48)
Comprehensive loss	$ (33,975)	$ (52,503)	$ (37,531)

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2014	27,547
Balance at Dec. 31, 2014	$ 152,351	$ (153)	$ (93,168)	$ 59,030
Net loss			(37,483)	(37,483)
Foreign currency translation adjustment		(48)		(48)
Issuance of common stock, net of issuance cost (in shares)	4,373
Issuance of common stock, net of issuance cost	$ 75,386			75,386
Issuance of common stock under stock option plan (in shares)	359
Issuance of common stock under stock option plan	$ 1,348			1,348
Stock subscription receivable	410			410
Share-based compensation expense	$ 4,407			4,407
Balance (in shares) at Dec. 31, 2015	32,279
Balance at Dec. 31, 2015	$ 233,902	(201)	(130,651)	103,050
Net loss			(52,761)	(52,761)
Foreign currency translation adjustment		258		258
Issuance of common stock, net of issuance cost (in shares)	145
Issuance of common stock, net of issuance cost	$ 1,808			1,808
Issuance of common stock under stock option plan (in shares)	204
Issuance of common stock under stock option plan	$ 1,136			1,136
Share-based compensation expense	$ 5,573			5,573
Balance (in shares) at Dec. 31, 2016	32,628
Balance at Dec. 31, 2016	$ 242,419	57	(183,412)	59,064
Net loss			(33,150)	(33,150)
Foreign currency translation adjustment		(825)		(825)
Issuance of common stock, net of issuance cost (in shares)	2,521
Issuance of common stock, net of issuance cost	$ 32,620			32,620
Issuance of common stock under stock option plan (in shares)	290
Issuance of common stock under stock option plan	$ 818			818
Share-based compensation expense	$ 1,635			1,635
Balance (in shares) at Dec. 31, 2017	35,439
Balance at Dec. 31, 2017	$ 277,492	$ (768)	$ (216,562)	$ 60,162

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Operating activities
Net loss	$ (33,150,000)	$ (52,761,000)	$ (37,483,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	1,484,000	698,000	699,000
Share-based compensation expense	1,750,000	5,573,000	4,407,000
Gain on disposal of property and equipment			(157,000)
Other non-cash adjustments	401,000
Changes in operating assets and liabilities:
Prepaid expenses and other current	1,041,000	(617,000)	(1,579,000)
Accounts payable	(2,700,000)	(981,000)	840,000
Accrued expenses	(2,470,000)	2,066,000	(52,000)
Deferred rent	(5,000)	7,000	17,000
Net cash used in operating activities	(33,649,000)	(46,015,000)	(33,308,000)
Investing activities
Purchase of property and equipment	(1,405,000)	(4,746,000)	(2,322,000)
Expenditures on building construction		(9,168,000)	(8,070,000)
Net cash used in investing activities	(1,405,000)	(13,914,000)	(10,392,000)
Financing activities
Issuance of common stock and warrants, net	32,620,000	1,808,000	75,712,000
Issuance of common stock under stock option plan	703,000	1,136,000	1,348,000
Collection of subscription receivable			410,000
Net cash provided by financing activities	33,323,000	2,944,000	77,470,000
Effect of foreign exchange rate on cash and cash equivalents	(825,000)	258,000	(48,000)
Net change in cash and cash equivalents	(2,556,000)	(56,727,000)	33,722,000
Cash and cash equivalents, beginning of period	34,324,000	91,051,000	57,329,000
Cash and cash equivalents, end of period	31,768,000	34,324,000	91,051,000
Supplemental Information:
Accrued purchases of property and equipment		148,000	940,000
Accrued expenditures on building construction		$ 439,000	$ 1,416,000

Note 1 - Organization

Note 1 - Organization	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. XBiotech Inc. (XBiotech or the Company) was incorporated in Canada on March 22, 2005. November 2007. August 2010. March 2013. January 2014. Since its inception, XBiotech has focused on advancing technology to rapidly identify and clone antibodies from individuals that have resistance to disease. At the heart of the Company is a proprietary technical knowhow to translate natural human immunity into therapeutic product candidates. In 2005, With the manufacturing capability to produce its True Human ™ 2010, first 2 The Company continues to be subject to a number of risks common to companies in similar stages of development. Principal among these risks are the uncertainties of technological innovations, dependence on key individuals, development of the same or similar technological innovations by the Company’s competitors and protection of proprietary technology. The Company’s ability to fund its planned clinical operations, including completion of its planned trials, is expected to depend on the amount and timing of cash receipts from future collaboration or product sales and/or financing transactions. The Company believes that its cash and cash equivalents of $31.8 December 31, 2017, one

Note 2 - Significant Accounting

Note 2 - Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Basis of Presentation These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (US GAAP). Basis of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions have been eliminated upon consolidation. Use of Estimates The preparation of financial statements in accordance with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported values of amounts in the financial statements and accompanying notes. Actual results could differ from those estimates. Prior to its initial public offering on April 15, 2015, third Research and Development Costs All research and development costs are charged to expense as incurred. Research and development costs include salaries and personnel-related costs, consulting fees, fees paid for contract clinical trial research services, the costs of laboratory consumables, equipment and facilities, license fees and other external costs. Costs incurred to acquire licenses for intellectual property to be used in research and development activities with no Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. Income Taxes The Company makes estimates and judgments in determining the need for a provision for income taxes, including the estimation of its taxable income or loss for the full fiscal year. The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating losses and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance. The Company may may The GAAP guidance requires recognition of the impact of a tax position in our financial statements only if that position is more likely than not Share-Based Compensation The Company accounts for its share-based compensation awards in accordance with ASC Topic 718, Compensation-Stock Compensation 718” 718, Share-based compensation expense recognized for the years ended December 31, 2017, 2016 2015 Year Ended 2017 2016 2015 Research and development $ 413 $ 2,095 $ 2,204 General and administrative 2,063 3,478 2,203 Total share-based compensation expense $ 2,476 $ 5,573 $ 4,407 No December 31, 2017, 2016 2015. The fair value of each option is estimated on the date of grant using the Black-Scholes method with the following assumptions: Year Ended 2017 2016 2015 Weighted-average grant date fair value per share $4.85 $7.29 $17.95 Expected volatility 65% - 67% 65% - 70% 66% - 71% Risk-free interest rate 1.83% - 2.41% 1.09% - 2.44% 1.07% - 2.42% Expected life (in years) 5.38 - 10 5 - 10 3 - 10 Dividend yield - - - Due to the adoption of ASU No. 2016 09, Cash and Cash Equivalents The Company considers highly liquid investments with a maturity of 90 Concentrations of Credit Risk Financial instruments that potentially subject the Company to credit risk consist primarily of cash and cash equivalents. The Company holds these investments in highly-rated financial institutions, and limits the amounts of credit exposure to any one may not not no Fair Value Measurements The Company follows ASC Topic 820, Fair Value Measurements and Disclosures three • Level 1—Unadjusted • Level 2—Quoted not • Level 3—Unobservable At December 31, 2017 2016, not December 31, 2017 2016, Property and Equipment Property and equipment, which consists of land, construction in process, furniture and fixtures, computers and office equipment, scientific equipment, leasehold improvements, vehicles and building are stated at cost and depreciated over the estimated useful lives of the assets, with the exception of land and construction in process which are not • Furniture and fixtures 7 • Office equipment 5 • Leasehold improvements Shorter of asset’s useful life or remaining lease term • Scientific equipment 5 • Vehicles 5 • Building 39 Costs of major additions and betterments are capitalized; maintenance and repairs, which do not Impairment of Long-Lived Assets The Company periodically evaluates its long-lived assets for potential impairment in accordance with ASC Topic 360, Property, Plant and Equipment may not not December 31, 2017. Foreign Currency Transactions Certain transactions are denominated in a currency other than the Company’s functional currency of the U.S. dollar, and the Company generates assets and liabilities that are fixed in terms of the amount of foreign currency that will be received or paid. At each balance sheet date, the Company adjusts the assets and liabilities to reflect the current exchange rate, resulting in a translation gain or loss. Transaction gains and losses are also realized upon a settlement of a foreign currency transaction in determining net loss for the period in which the transaction is settled. Comprehensive Income (Loss) ASC Topic 220, Comprehensive Income Segment and Geographic Information Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision making group, in making decisions on how to allocate resources and assess performance. The Company’s chief operating decision maker is the Chief Executive Officer. The Company and the chief operating decision maker view the Company’s operations and manage its business as one Net Loss per Share Net loss per share (“EPS”) is computed by dividing net loss by the weighted average number of common shares outstanding during each period. Diluted EPS is computed by dividing net loss by the weighted average number of common shares and common share equivalents outstanding (if dilutive) during each period. The number of common share equivalents, which include stock options, is computed using the treasury stock method. Subsequent Events The Company considered events or transactions occurring after the balance sheet date but prior to the date the consolidated financial statements are available to be issued for potential recognition or disclosure in its consolidated financial statements. We have evaluated subsequent events through the date of filing this Form 10 Recent Accounting Pronouncements In February 2016, No. 2016 02, 2016 02. not 2019, 2020, 2021. In March 2016, No. 2016 09, January 1, 2017. $491 not not $491 2016 09 no January 1, 2017. one not

Note 3 - Property and Equipment

Note 3 - Property and Equipment and Building Construction in Progress	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	3. Property and equipment consisted of the following as of December 31, 2017 2016 2017 2016 Computer and office equipment $ 461 $ 456 Furniture and fixtures 183 132 Land 1,418 1,418 Leasehold improvements 802 794 Scientific equipment 12,194 6,116 Vehicle 30 30 Building 21,013 19,978 Construction in process 472 6,645 Accumulated depreciation (6,933 ) (5,449 ) Total $ 29,640 $ 30,120 Depreciation expenses related to property and equipment amounted to approximately $1,484,000, $698,000, $699,000 December 31, 2017, 2016 2015,

Note 4 - Accrued Expenses

Note 4 - Accrued Expenses	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	4. Accrued expenses consist of the following as of December 31, 2017, 2016 2017 2016 Accrued compensation and related expenses $ 234 $ 413 Accrued professional fees 32 95 Accrued building construction fees - 521 Accrued clinical trial expenses 766 2,402 Other 30 101 Total $ 1,062 $ 3,532

Note 5 - Common Stock

Note 5 - Common Stock	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	5. Pursuant to its Articles, the Company has an unlimited number of shares available for issuance with no From January December 2016, 204 $0.74 $19.09 $1.1 From November December 2016, 145 $13.60 $14.17 $1.8 In February 2017, 87 $12.09 $12.37 $1.0 In March 2017, 2.4 $13.00 $31.6 From January December 2017, 290 $2.50 $14.71 $703

Note 6 - Common Stock Options

Note 6 - Common Stock Options	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	6. On November 11, 2005, may may All options will be non-transferable and may first may The term of the options is at the discretion of the Compensation Committee, but may not 10 three The number of common shares reserved for issuance to any one not, 5% A summary of changes in common stock options issued under the Plan is as follows: Options Exercise Price Weighted-Average Options outstanding at December 31, 2014 4,884,165 $0.55 - $15.00 $ 7.03 Granted 375,928 8.47 - 21.99 17.95 Exercised (359,141 ) 0.53 - 10.00 3.75 Forfeitures (114,375 ) 0.55 - 20.93 11.05 Options outstanding at December 31, 2015 4,786,577 $0.53 - $21.99 $ 8.56 Granted 1,059,990 7.71 - 19.10 11.72 Exercised (204,159 ) 0.74 - 19.09 5.56 Forfeitures (453,750 ) 0.52 - 16.91 12.79 Options outstanding at December 31, 2016 5,188,658 $0.52 - $21.99 $ 8.49 Granted 1,251,000 4.15 - 12.62 4.85 Exercised (406,667 ) 0.93 - 14.71 2.28 Forfeitures (729,367 ) 0.94 - 21.99 11.90 Options outstanding at December 31, 2017 5,303,624 $2.5 - $21.99 $ 7.69 The weighted average fair value of the options issued to directors, employees and consultants during the fiscal years ended December 31, 2017, 2016 2015, $2.97, $7.29 $17.95, 3.75 $1.63 $2.86, 2017, 2016 2015, December 31, 2017 $746,000. December 31, 2017, 2016 2015 $1,601,000, $5,728,000and $5,463,000, As of December 31, 2017, $3.1 2.23

Note 7 - Net Loss Per Share

Note 7 - Net Loss Per Share	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Earnings Per Share [Text Block]	7. The following summarizes the computation of basic and diluted net loss per share for the years ended December 31, 2017, 2016 2015 Year Ended December 31, 2017 2016 2015 Net loss $ (33,150 ) $ (52,761 ) $ (37,483 ) Weighted-average number of common shares—basic and diluted 34,875,814 32,403,391 30,801,994 Net loss per share—basic and diluted $ (0.95 ) $ (1.63 ) $ (1.22 ) The following potentially dilutive securities outstanding, prior to the use of the treasury stock method or if-converted method, have been excluded from the computation of diluted weighted-average common shares outstanding, because including them would have had an anti-dilutive effect due to the losses reported. Year Ended December 31, 2017 2016 2015 Stock options 5,303,624 5,188,658 4,786,577 Warrants to purchase common stock - - - Total 5,303,624 5,188,658 4,786,577

Note 8 - Income Taxes

Note 8 - Income Taxes	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Income Tax Disclosure [Text Block]	8. The Company recorded no December 31, 2017, 2016 2015 A reconciliation of the Company’s Canadian federal statutory income tax rate to the Company’s effective income tax rate is as follows for the years ended December 31, 2017, 2016 2015: 2017 2016 2015 Income tax benefit computed at federal tax rate 26.0 % 26.0 % 26.0 % Change in valuation allowance (15.3 %) (22.1 %) (27.2 %) Impacts of US tax reform (13.4 %) - - Stock compensation and other 2.7 % (3.9 %) 1.2 % Total — % — % — % During the years ended December 31, 2017, 2016 2015, no As of December 31, 2017, 2016, $167.6 $132.3 $27.7 $6.7 $0.9 $133.0 $108.9 $18.6 $4.8 $0.6 2025 2028 2034 2018 2022 Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company has established a valuation allowance due to uncertainties regarding the realization of deferred tax assets based upon the Company’s lack of earnings history. Significant components of the Company’s deferred tax assets and liabilities as of December 31, 2017, 2016 2015 2017 2016 2015 Deferred tax assets: Noncapital losses $ 41,551 $ 35,064 $ 23,038 Qualifying research and development credits 2,833 2,408 1,591 Stock based compensation 1,618 2,737 3,982 Share issue costs 42 27 30 Accrued liabilities 49 286 356 Deferred rent 4 8 6 Total deferred tax assets 46,097 40,530 29,003 Deferred tax liabilities: Depreciation 282 31 13 Share issuance costs 35 16 23 Total deferred tax liabilities 317 47 36 Net deferred tax asset 45,780 40,483 28,967 Valuation allowance for deferred tax assets (45,780 ) (40,483 ) (28,967 ) Net deferred tax asset including valuation allowance $ — $ — $ — On December 22, 2017, 34 21 January 1, 2018. 21 $4.5 no As the Company does not not not not 740 no fourth 2018. Due to additional current year losses, offset by the decrease of the U.S. tax rate from 34% 21% 2017, $5.3 $11.5 December 31, 2017 2016 The Company applies the accounting guidance in ASC 740 not December 31, 2017 2016, no The Company files federal income tax returns in Canada, U.S, Switzerland, Germany, and Japan. The Company also files income tax returns in the state of Texas in the U.S. The statute of limitations for assessment by local taxing authorities is open for tax years ended after December 2011. no The components of income before income taxes are as follows: (In thousands) Years Ended December 31, 2017 2016 2015 Domestic $ (5,765 ) $ (8,749 ) $ (6,544 ) Canada (26,034 ) (41,625 ) (28,129 ) Other Foreign (1,351 ) (2,387 ) (2,810 ) Total $ (33,150 ) $ (52,761 ) $ (37,483 ) In November 2015, 2015 17, three December 31, 2016. not

Note 9 - Commitments and Contin

Note 9 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Commitments Disclosure [Text Block]	9. On January 12, 2008, September 15, 2010, second March 20, 2013, 21 February 28, 2015, four two December 31, 2017 2018 $ 470 2019 $ 79 Rent expense was approximately $741,000, $761,000 $688,000 December 31, 2017, 2016 2015, XBiotech Corporate officers, Queena Han (VP of Finance) and John Simard (President and CEO), XBiotech Inc., and certain directors were named defendants in securities class action civil suits filed in federal court at the U.S. District Court for the Western District of Texas, in Austin, Texas and state court at the Los Angeles County Superior Court, in California. In the California action, the underwriter WR Hambrecht & Co., LLC was also named as a defendant. These civil suits were filed on December 1, 2015. April 2015. November 23, 2015, September 2016, not October 2016. June 7, 2017. not The plaintiffs re-filed their suit in Travis County district court, located in Austin, Texas, on July 6, 2017. October 6, 2017, 1933 November 2017. first 2018, may

Note 10 - Subsequent Events

Note 10 - Subsequent Events	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Subsequent Events [Text Block]	10. On January 16, 2018, January 16th, 2018, 6505 1 5605 2 45 As described in a Form 8 March 1, 2018, February 27, 2018, Jan- no January 18, 2018 8 January 19, 2018. November 9, 2017 10 November 8, 2018 5605.

Note 11 - Selected Quarterly Fi

Note 11 - Selected Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Quarterly Financial Information [Text Block]	11. Selected Quarterly Financial Data (Unaudited) for the year ended December 31, 2017 2016 2017 First Quarter Second Quarter Third Quarter Fourth Quarter Loss from operations (10,271 ) (9,688 ) (6,593 ) (7,507 ) Net Loss (10,563 ) (9,133 ) (6,205 ) (7,249 ) Net loss per share—basic and diluted (0.32 ) (0.26 ) (0.18 ) (0.20 ) 2016 First Quarter Second Quarter Third Quarter Fourth Quarter Loss from operations (10,248 ) (13,615 ) (12,459 ) (16,441 ) Net Loss (10,257 ) (13,622 ) (12,484 ) (16,398 ) Net loss per share—basic and diluted (0.32 ) (0.42 ) (0.38 ) (0.50 )

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (US GAAP).
Consolidation, Policy [Policy Text Block]	Basis of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions have been eliminated upon consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in accordance with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported values of amounts in the financial statements and accompanying notes. Actual results could differ from those estimates. Prior to its initial public offering on April 15, 2015, third
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs All research and development costs are charged to expense as incurred. Research and development costs include salaries and personnel-related costs, consulting fees, fees paid for contract clinical trial research services, the costs of laboratory consumables, equipment and facilities, license fees and other external costs. Costs incurred to acquire licenses for intellectual property to be used in research and development activities with no Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company makes estimates and judgments in determining the need for a provision for income taxes, including the estimation of its taxable income or loss for the full fiscal year. The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating losses and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance. The Company may may The GAAP guidance requires recognition of the impact of a tax position in our financial statements only if that position is more likely than not
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Share-Based Compensation The Company accounts for its share-based compensation awards in accordance with ASC Topic 718, Compensation-Stock Compensation 718” 718, Share-based compensation expense recognized for the years ended December 31, 2017, 2016 2015 Year Ended 2017 2016 2015 Research and development $ 413 $ 2,095 $ 2,204 General and administrative 2,063 3,478 2,203 Total share-based compensation expense $ 2,476 $ 5,573 $ 4,407 No December 31, 2017, 2016 2015. The fair value of each option is estimated on the date of grant using the Black-Scholes method with the following assumptions: Year Ended 2017 2016 2015 Weighted-average grant date fair value per share $4.85 $7.29 $17.95 Expected volatility 65% - 67% 65% - 70% 66% - 71% Risk-free interest rate 1.83% - 2.41% 1.09% - 2.44% 1.07% - 2.42% Expected life (in years) 5.38 - 10 5 - 10 3 - 10 Dividend yield - - - Due to the adoption of ASU No. 2016 09,
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers highly liquid investments with a maturity of 90
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk Financial instruments that potentially subject the Company to credit risk consist primarily of cash and cash equivalents. The Company holds these investments in highly-rated financial institutions, and limits the amounts of credit exposure to any one may not not no
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements The Company follows ASC Topic 820, Fair Value Measurements and Disclosures three • Level 1—Unadjusted • Level 2—Quoted not • Level 3—Unobservable At December 31, 2017 2016, not December 31, 2017 2016,
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment, which consists of land, construction in process, furniture and fixtures, computers and office equipment, scientific equipment, leasehold improvements, vehicles and building are stated at cost and depreciated over the estimated useful lives of the assets, with the exception of land and construction in process which are not • Furniture and fixtures 7 • Office equipment 5 • Leasehold improvements Shorter of asset’s useful life or remaining lease term • Scientific equipment 5 • Vehicles 5 • Building 39 Costs of major additions and betterments are capitalized; maintenance and repairs, which do not
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets The Company periodically evaluates its long-lived assets for potential impairment in accordance with ASC Topic 360, Property, Plant and Equipment may not not December 31, 2017.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Transactions Certain transactions are denominated in a currency other than the Company’s functional currency of the U.S. dollar, and the Company generates assets and liabilities that are fixed in terms of the amount of foreign currency that will be received or paid. At each balance sheet date, the Company adjusts the assets and liabilities to reflect the current exchange rate, resulting in a translation gain or loss. Transaction gains and losses are also realized upon a settlement of a foreign currency transaction in determining net loss for the period in which the transaction is settled.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Income (Loss) ASC Topic 220, Comprehensive Income
Segment Reporting, Policy [Policy Text Block]	Segment and Geographic Information Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision making group, in making decisions on how to allocate resources and assess performance. The Company’s chief operating decision maker is the Chief Executive Officer. The Company and the chief operating decision maker view the Company’s operations and manage its business as one
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share Net loss per share (“EPS”) is computed by dividing net loss by the weighted average number of common shares outstanding during each period. Diluted EPS is computed by dividing net loss by the weighted average number of common shares and common share equivalents outstanding (if dilutive) during each period. The number of common share equivalents, which include stock options, is computed using the treasury stock method.
Subsequent Events, Policy [Policy Text Block]	Subsequent Events The Company considered events or transactions occurring after the balance sheet date but prior to the date the consolidated financial statements are available to be issued for potential recognition or disclosure in its consolidated financial statements. We have evaluated subsequent events through the date of filing this Form 10
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In February 2016, No. 2016 02, 2016 02. not 2019, 2020, 2021. In March 2016, No. 2016 09, January 1, 2017. $491 not not $491 2016 09 no January 1, 2017. one not

Note 2 - Significant Accounti20

Note 2 - Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Year Ended 2017 2016 2015 Research and development $ 413 $ 2,095 $ 2,204 General and administrative 2,063 3,478 2,203 Total share-based compensation expense $ 2,476 $ 5,573 $ 4,407
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended 2017 2016 2015 Weighted-average grant date fair value per share $4.85 $7.29 $17.95 Expected volatility 65% - 67% 65% - 70% 66% - 71% Risk-free interest rate 1.83% - 2.41% 1.09% - 2.44% 1.07% - 2.42% Expected life (in years) 5.38 - 10 5 - 10 3 - 10 Dividend yield - - -

Note 3 - Property and Equipme21

Note 3 - Property and Equipment and Building Construction in Progress (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Property, Plant and Equipment [Table Text Block]	2017 2016 Computer and office equipment $ 461 $ 456 Furniture and fixtures 183 132 Land 1,418 1,418 Leasehold improvements 802 794 Scientific equipment 12,194 6,116 Vehicle 30 30 Building 21,013 19,978 Construction in process 472 6,645 Accumulated depreciation (6,933 ) (5,449 ) Total $ 29,640 $ 30,120

Note 4 - Accrued Expenses (Tabl

Note 4 - Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	2017 2016 Accrued compensation and related expenses $ 234 $ 413 Accrued professional fees 32 95 Accrued building construction fees - 521 Accrued clinical trial expenses 766 2,402 Other 30 101 Total $ 1,062 $ 3,532

Note 6 - Common Stock Options (

Note 6 - Common Stock Options (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Share-based Compensation, Stock Options, Activity [Table Text Block]	Options Exercise Price Weighted-Average Options outstanding at December 31, 2014 4,884,165 $0.55 - $15.00 $ 7.03 Granted 375,928 8.47 - 21.99 17.95 Exercised (359,141 ) 0.53 - 10.00 3.75 Forfeitures (114,375 ) 0.55 - 20.93 11.05 Options outstanding at December 31, 2015 4,786,577 $0.53 - $21.99 $ 8.56 Granted 1,059,990 7.71 - 19.10 11.72 Exercised (204,159 ) 0.74 - 19.09 5.56 Forfeitures (453,750 ) 0.52 - 16.91 12.79 Options outstanding at December 31, 2016 5,188,658 $0.52 - $21.99 $ 8.49 Granted 1,251,000 4.15 - 12.62 4.85 Exercised (406,667 ) 0.93 - 14.71 2.28 Forfeitures (729,367 ) 0.94 - 21.99 11.90 Options outstanding at December 31, 2017 5,303,624 $2.5 - $21.99 $ 7.69

Note 7 - Net Loss Per Share (Ta

Note 7 - Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year Ended December 31, 2017 2016 2015 Net loss $ (33,150 ) $ (52,761 ) $ (37,483 ) Weighted-average number of common shares—basic and diluted 34,875,814 32,403,391 30,801,994 Net loss per share—basic and diluted $ (0.95 ) $ (1.63 ) $ (1.22 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Year Ended December 31, 2017 2016 2015 Stock options 5,303,624 5,188,658 4,786,577 Warrants to purchase common stock - - - Total 5,303,624 5,188,658 4,786,577

Note 8 - Income Taxes (Tables)

Note 8 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2017 2016 2015 Income tax benefit computed at federal tax rate 26.0 % 26.0 % 26.0 % Change in valuation allowance (15.3 %) (22.1 %) (27.2 %) Impacts of US tax reform (13.4 %) - - Stock compensation and other 2.7 % (3.9 %) 1.2 % Total — % — % — %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2017 2016 2015 Deferred tax assets: Noncapital losses $ 41,551 $ 35,064 $ 23,038 Qualifying research and development credits 2,833 2,408 1,591 Stock based compensation 1,618 2,737 3,982 Share issue costs 42 27 30 Accrued liabilities 49 286 356 Deferred rent 4 8 6 Total deferred tax assets 46,097 40,530 29,003 Deferred tax liabilities: Depreciation 282 31 13 Share issuance costs 35 16 23 Total deferred tax liabilities 317 47 36 Net deferred tax asset 45,780 40,483 28,967 Valuation allowance for deferred tax assets (45,780 ) (40,483 ) (28,967 ) Net deferred tax asset including valuation allowance $ — $ — $ —
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	(In thousands) Years Ended December 31, 2017 2016 2015 Domestic $ (5,765 ) $ (8,749 ) $ (6,544 ) Canada (26,034 ) (41,625 ) (28,129 ) Other Foreign (1,351 ) (2,387 ) (2,810 ) Total $ (33,150 ) $ (52,761 ) $ (37,483 )

Note 9 - Commitments and Cont26

Note 9 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	2018 $ 470 2019 $ 79

Note 11 - Selected Quarterly 27

Note 11 - Selected Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Quarterly Financial Information [Table Text Block]	2017 First Quarter Second Quarter Third Quarter Fourth Quarter Loss from operations (10,271 ) (9,688 ) (6,593 ) (7,507 ) Net Loss (10,563 ) (9,133 ) (6,205 ) (7,249 ) Net loss per share—basic and diluted (0.32 ) (0.26 ) (0.18 ) (0.20 ) 2016 First Quarter Second Quarter Third Quarter Fourth Quarter Loss from operations (10,248 ) (13,615 ) (12,459 ) (16,441 ) Net Loss (10,257 ) (13,622 ) (12,484 ) (16,398 ) Net loss per share—basic and diluted (0.32 ) (0.42 ) (0.38 ) (0.50 )

Note 1 - Organization (Details

Note 1 - Organization (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Cash and Cash Equivalents, at Carrying Value	$ 31,768	$ 34,324	$ 91,051	$ 57,329

Note 2 - Significant Accounti29

Note 2 - Significant Accounting Policies (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Jan. 01, 2017USD ($)
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense	$ 0	$ 0	$ 0
Assets, Fair Value Disclosure, Recurring	0	0
Liabilities, Fair Value Disclosure, Recurring	0	0
Impairment of Long-Lived Assets Held-for-use	$ 0
Number of Operating Segments	1
Deferred Tax Assets, Gross	$ 46,097	40,530	29,003
Deferred Tax Assets, Valuation Allowance	$ 45,780	$ 40,483	$ 28,967
Accounting Standards Update 2016-09 [Member]
Deferred Tax Assets, Gross				$ 491
Deferred Tax Assets, Valuation Allowance				$ 491
Furniture and Fixtures [Member]
Property, Plant and Equipment, Useful Life	7 years
Office Equipment [Member]
Property, Plant and Equipment, Useful Life	5 years
Equipment [Member]
Property, Plant and Equipment, Useful Life	5 years
Vehicles [Member]
Property, Plant and Equipment, Useful Life	5 years
Building [Member]
Property, Plant and Equipment, Useful Life	39 years

Note 2 - Significant Accounti30

Note 2 - Significant Accounting Policies - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based compensation expense	$ 2,476	$ 5,573	$ 4,407
Research and Development Expense [Member]
Share-based compensation expense	413	2,095	2,204
General and Administrative Expense [Member]
Share-based compensation expense	$ 2,063	$ 3,478	$ 2,203

Note 2 - Significant Accounti31

Note 2 - Significant Accounting Policies - Stock Option Valuation Assumptions (Details) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Weighted-average grant date fair value per share (in dollars per share)	$ 4.85	$ 7.29	$ 17.95
Dividend yield
Minimum [Member]
Expected volatility	65.00%	65.00%	66.00%
Risk-free interest rate	1.83%	1.09%	1.07%
Expected life (in years) (Year)	5 years 138 days	5 years	3 years
Maximum [Member]
Expected volatility	67.00%	70.00%	71.00%
Risk-free interest rate	2.41%	2.44%	2.42%
Expected life (in years) (Year)	10 years	10 years	10 years

Note 3 - Property and Equipme32

Note 3 - Property and Equipment and Building Construction in Progress (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Depreciation	$ 1,484,000	$ 698,000	$ 699,000

Note 3 - Property and Equipme33

Note 3 - Property and Equipment and Building Construction in Progress - Property and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Accumulated depreciation	$ (6,933)	$ (5,449)
Total	29,640	30,120
Office Equipment [Member]
Property, plant, and equipment, gross	461	456
Furniture and Fixtures [Member]
Property, plant, and equipment, gross	183	132
Land [Member]
Property, plant, and equipment, gross	1,418	1,418
Leasehold Improvements [Member]
Property, plant, and equipment, gross	802	794
Scientific Equipment [Member]
Property, plant, and equipment, gross	12,194	6,116
Vehicles [Member]
Property, plant, and equipment, gross	30	30
Building [Member]
Property, plant, and equipment, gross	21,013	19,978
Construction in Progress [Member]
Property, plant, and equipment, gross	$ 472	$ 6,645

Note 4 - Accrued Expenses - Acc

Note 4 - Accrued Expenses - Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Accrued compensation and related expenses	$ 234	$ 413
Accrued professional fees	32	95
Accrued building construction fees		521
Accrued clinical trial expenses	766	2,402
Other	30	101
Total	$ 1,062	$ 3,532

Note 5 - Common Stock (Details

Note 5 - Common Stock (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		2 Months Ended	12 Months Ended
	Mar. 31, 2017	Feb. 28, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Common Stock, No Par Value			$ 0	$ 0	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period				406,667	204,159	359,141
Proceeds from Stock Options Exercised				$ 703	$ 1,100
Stock Issued During Period, Shares, New Issues	2,400,000	87,000	145,000
Proceeds from Issuance of Common Stock	$ 31,600	$ 1,000	$ 1,800
Shares Issued, Price Per Share	$ 13
Minimum [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price				$ 2.50	$ 0.74	$ 0.53
Share Price			$ 13.60		13.60
Shares Issued, Price Per Share		$ 12.09
Maximum [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price				$ 14.71	19.09	$ 10
Share Price			$ 14.17		$ 14.17
Shares Issued, Price Per Share		$ 12.37

Note 6 - Common Stock Options36

Note 6 - Common Stock Options (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 4.85	$ 7.29	$ 17.95
The Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	2.97	7.29	17.95
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Intrinsic Value, Amount Per Share	$ 3.75	$ 1.63	$ 2.86
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	$ 746,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	1,601,000	$ 5,728,000	$ 5,463,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 3,100,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 83 days
The Plan [Member] | Any One Person [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum	5.00%
The Plan [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years

Note 6 - Common Stock Options -

Note 6 - Common Stock Options - Changes in Common Stock Options Issued (Details) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Options outstanding (in shares)	5,188,658	4,786,577	4,884,165
Granted (in shares)	1,251,000	1,059,990	375,928
Exercised (in shares)	(406,667)	(204,159)	(359,141)
Forfeitures (in shares)	(729,367)	(453,750)	(114,375)
Options outstanding (in shares)	5,303,624	5,188,658	4,786,577
Minimum [Member]
Options outstanding, exercise price (in dollars per share)	$ 0.52	$ 0.53	$ 0.55
Granted (in dollars per share)	4.15	7.71	8.47
Exercised (in dollars per share)	2.50	0.74	0.53
Forfeitures (in dollars per share)	0.94	0.52	0.55
Options outstanding, exercise price (in dollars per share)	2.50	0.52	0.53
Maximum [Member]
Options outstanding, exercise price (in dollars per share)	21.99	21.99	15
Granted (in dollars per share)	12.62	19.10	21.99
Exercised (in dollars per share)	14.71	19.09	10
Forfeitures (in dollars per share)	21.99	16.91	20.93
Options outstanding, exercise price (in dollars per share)	21.99	21.99	21.99
Weighted Average [Member]
Options outstanding, exercise price (in dollars per share)	8.49	8.56	7.03
Granted (in dollars per share)	4.85	11.72	17.95
Exercised (in dollars per share)	2.28	5.56	3.75
Forfeitures (in dollars per share)	11.90	12.79	11.05
Options outstanding, exercise price (in dollars per share)	$ 7.69	$ 8.49	$ 8.56

Note 7 - Net Loss Per Share - C

Note 7 - Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Net loss	$ (7,249)	$ (6,205)	$ (9,133)	$ (10,563)	$ (16,398)	$ (12,484)	$ (13,622)	$ (10,257)	$ (33,150)	$ (52,761)	$ (37,483)
Weighted-average number of common shares—basic and diluted (in shares)									34,875,814	32,403,391	30,801,994
Net loss per share—basic and diluted (in dollars per share)	$ (0.20)	$ (0.18)	$ (0.26)	$ (0.32)	$ (0.50)	$ (0.38)	$ (0.42)	$ (0.32)	$ (0.95)	$ (1.63)	$ (1.22)

Note 7 - Net Loss Per Share - P

Note 7 - Net Loss Per Share - Potentially Dilutive Securities Outstanding (Details) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Antidilutive securities (in shares)	5,303,624	5,188,658	4,786,577
Employee Stock Option [Member]
Antidilutive securities (in shares)	5,303,624	5,188,658	4,786,577
Warrant [Member]
Antidilutive securities (in shares)

Note 8 - Income Taxes (Details

Note 8 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Expense (Benefit)		$ 0	$ 0	$ 0
Income Tax Examination, Penalties and Interest Expense		0	0	$ 0
Operating Loss Carryforwards		167,600	$ 133,000
Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability		$ 4,500
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		26.00%	26.00%	26.00%
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount		$ 5,300	$ 11,500
Unrecognized Tax Benefits		0	0
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount		(4,500)
Scenario, Forecast [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%
Domestic Tax Authority [Member]
Operating Loss Carryforwards				$ 108,900
Domestic Tax Authority [Member] | Canada Revenue Agency [Member]
Operating Loss Carryforwards		132,300	108,300	18,600
Foreign Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards		27,700	18,700	$ 4,800
Foreign Tax Authority [Member] | Federal Ministry of Finance, Germany [Member]
Operating Loss Carryforwards		6,700	5,700
Foreign Tax Authority [Member] | Swiss Federal Tax Administration (FTA) [Member]
Operating Loss Carryforwards		900	600
Foreign Tax Authority [Member] | National Tax Agency, Japan [Member]
Operating Loss Carryforwards		$ 900	$ 600

Note 8 - Income Taxes - Reconci

Note 8 - Income Taxes - Reconciliation of Canadian Federal Statutory Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income tax benefit computed at federal tax rate	26.00%	26.00%	26.00%
Change in valuation allowance	(15.30%)	(22.10%)	(27.20%)
Impacts of US tax reform	(13.40%)
Stock compensation and other	2.70%	(3.90%)	1.20%
Total

Note 8 - Income Taxes - Signifi

Note 8 - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets:
Noncapital losses	$ 41,551	$ 35,064	$ 23,038
Qualifying research and development credits	2,833	2,408	1,591
Stock based compensation	1,618	2,737	3,982
Share issue costs	42	27	30
Accrued liabilities	49	286	356
Deferred rent	4	8	6
Total deferred tax assets	46,097	40,530	29,003
Deferred tax liabilities:
Depreciation	282	31	13
Share issuance costs	35	16	23
Total deferred tax liabilities	317	47	36
Net deferred tax asset	45,780	40,483	28,967
Valuation allowance for deferred tax assets	(45,780)	(40,483)	(28,967)
Net deferred tax asset including valuation allowance

Note 8 - Income Taxes - Compone

Note 8 - Income Taxes - Components of Income Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Domestic	$ (5,765)	$ (8,749)	$ (6,544)
Total	(33,150)	(52,761)	(37,483)
CANADA
Canada	(26,034)	(41,625)	(28,129)
Other Foreign [Member]
Canada	$ (1,351)	$ (2,387)	$ (2,810)

Note 9 - Commitments and Cont44

Note 9 - Commitments and Contingencies (Details Textual) - USD ($)	Feb. 28, 2015	Mar. 20, 2013	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Lessee, Operating Lease, Renewal Term	4 years	1 year 270 days
Lessee Leasing Arrangements, Operating Leases, Early Termination Right	2 years
Operating Leases, Rent Expense, Net			$ 741,000	$ 761,000	$ 688,000

Note 9 - Future Minimum Lease P

Note 9 - Future Minimum Lease Payments for Operating Leases (Details) $ in Thousands	Dec. 31, 2017USD ($)
2,018	$ 470
2,019	$ 79

Note 11 - Selected Quarterly 46

Note 11 - Selected Quarterly Financial Data (Unaudited) - Quarterly Financial Data (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Loss from operations	$ (7,507)	$ (6,593)	$ (9,688)	$ (10,271)	$ (16,441)	$ (12,459)	$ (13,615)	$ (10,248)	$ (34,059)	$ (52,763)	$ (37,510)
Net Loss	$ (7,249)	$ (6,205)	$ (9,133)	$ (10,563)	$ (16,398)	$ (12,484)	$ (13,622)	$ (10,257)	$ (33,150)	$ (52,761)	$ (37,483)
Net loss per share—basic and diluted (in dollars per share)	$ (0.20)	$ (0.18)	$ (0.26)	$ (0.32)	$ (0.50)	$ (0.38)	$ (0.42)	$ (0.32)	$ (0.95)	$ (1.63)	$ (1.22)